Chikungunya
A mosquito-borne viral illness that typically causes sudden fever and severe joint pain, which can persist for months or years in some patients.
What causes Chikungunya?
Chikungunya is caused by chikungunya virus, an alphavirus spread mainly through bites from infected Aedes aegypti and Aedes albopictus mosquitoes. It does not spread through ordinary contact, coughing, or sneezing.
Symptoms and what to notice
Sudden high fever and severe, often symmetric joint pain are typical. Other symptoms can include joint swelling, headache, muscle pain, fatigue, rash, nausea, or conjunctivitis. Rare complications can affect the brain, heart, liver, kidneys, eyes, or other organs.
How long can it last?
Symptoms usually begin 3 to 7 days after an infected mosquito bite, with a possible range of 1 to 12 days. Acute illness commonly improves within 7 to 10 days, but joint pain or arthritis can persist or recur for months or years.
How serious is Chikungunya?
Death is uncommon, but newborns infected around delivery, adults older than 65, and people with hypertension, diabetes, cardiovascular disease, or other conditions have greater risk of severe disease. Neurologic, cardiac, eye, liver, kidney, and other complications can occur.
Treatment and management
No chikungunya-specific antiviral is available. Care includes rest, fluids, and treatment of pain and fever. Because chikungunya can resemble dengue, acetaminophen is preferred initially and aspirin or NSAIDs should be avoided until dengue is ruled out. Persistent joint symptoms may need clinician-directed anti-inflammatory treatment and physical therapy.
Vaccine: who and when?
Product: VIMKUNYA, a non-live recombinant virus-like particle vaccine given as one 0.8 mL intramuscular dose for eligible people age 12 and older. CDC recommends it for travelers to outbreak areas and laboratory workers with potential exposure; it may be considered for extended stays in elevated-risk areas. No booster is currently recommended. IXCHIQ is no longer available under its former U.S. approval after safety-related license suspension, manufacturer discontinuation, and withdrawal of accelerated approval.
Cost note: Vaccine price, administration fees, insurance coverage, and travel-clinic charges vary. Travelers should ask the vaccinating clinic and insurer for a current estimate before the visit.
Trusted source
Patient cost varies by insurance, provider, location, and eligibility. Coverage and public-health access differ, so listed prices are examples rather than guaranteed patient prices. This page is for general education and does not replace individualized medical advice, diagnosis, vaccination assessment, or treatment.
Chikungunya: History, Symptoms, Transmission, Treatment, Prevention, and Vaccine Information
Chikungunya is a mosquito-borne viral disease best known for causing a sudden fever and sometimes extremely severe joint pain. The infection is caused by chikungunya virus, commonly abbreviated CHIKV, and is transmitted primarily through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes.
Most people infected with chikungunya virus develop symptoms. The illness usually begins abruptly and can cause:
- High fever
- Severe joint pain
- Joint swelling
- Headache
- Muscle pain
- Fatigue
- Rash
- Nausea
- Eye redness or conjunctivitis
The acute illness usually improves within approximately one week, but chikungunya differs from many other mosquito-borne infections because joint pain can persist for months or even years after the original infection. In some patients, chronic joint disease becomes the most disabling consequence of the infection.
Deaths are uncommon, but serious neurological, cardiac, liver, kidney, eye, and other complications can occur.
The greatest risk of severe disease occurs among groups including:
- Newborns infected around the time of delivery
- Adults aged 65 years and older
- People with hypertension
- People with diabetes
- People with cardiovascular disease
- Some immunocompromised individuals
Chikungunya has expanded dramatically from its historically recognized areas in Africa and Asia. Local transmission has now been documented in more than 100 countries and territories, including parts of the Americas and Europe. WHO reported substantial renewed global activity during 2025 and classified the global public-health risk from chikungunya as moderate in an April 2026 rapid risk assessment.
Unlike in previous decades, a chikungunya vaccine is now available in the United States for selected people at increased risk. As of 2026, the currently available U.S. vaccine is VIMKUNYA, a non-live virus-like particle vaccine approved for people aged 12 years and older.
Important: This article is intended for general education. People with suspected chikungunya should receive medical advice, particularly because chikungunya can resemble dengue, which requires different precautions and can cause serious bleeding.
What Is Chikungunya?
Chikungunya is an infection caused by chikungunya virus, an RNA virus belonging to:
- Family: Togaviridae
- Genus: Alphavirus
The virus is an enveloped virus containing a single-stranded RNA genome.
Chikungunya virus particles are approximately 60 to 70 nanometers in diameter and contain an icosahedral capsid surrounded by a lipid envelope.
Alphaviruses can produce different types of disease.
Some mainly cause neurological disease.
Others, including chikungunya virus, are particularly associated with:
- Joint pain
- Arthritis
- Musculoskeletal inflammation
The ability of chikungunya to produce prolonged joint symptoms is one of its defining clinical characteristics.
Chikungunya Quick Facts
| Feature | Information |
|---|---|
| Disease | Chikungunya |
| Virus | Chikungunya virus, CHIKV |
| Virus family | Togaviridae |
| Virus genus | Alphavirus |
| Genetic material | Single-stranded RNA |
| Primary transmission | Infected mosquito bites |
| Main mosquito vectors | Aedes aegypti and Aedes albopictus |
| Typical incubation period | Approximately 3 to 7 days |
| Possible incubation range | Approximately 1 to 12 days |
| Main symptoms | Fever and severe joint pain |
| Chronic joint pain | Can persist for months or years |
| Person-to-person respiratory spread | No |
| Pregnancy transmission | Possible, especially around delivery |
| Specific antiviral treatment | None currently approved |
| Vaccine available in U.S. | Yes |
| Current U.S. vaccine | VIMKUNYA |
| Approved U.S. age | 12 years and older |
| Vaccine doses | One dose |
| Booster recommendation | None currently |
| Main prevention | Vaccination when indicated and mosquito-bite prevention |
The History of Chikungunya
The history of chikungunya demonstrates how a mosquito-borne virus can remain relatively localized for decades and then spread across continents as mosquito populations, international travel, urbanization, and viral evolution interact.
Although chikungunya was formally identified during the twentieth century, historical evidence suggests that similar outbreaks may have occurred much earlier and were sometimes mistaken for dengue.
1952 to 1953: The First Recognized Chikungunya Outbreak
The first clearly recognized outbreak of chikungunya occurred in southern Tanzania, then known as Tanganyika, during 1952 and 1953.
Patients developed:
- Sudden fever
- Rash
- Severe joint pain
- Persistent arthralgia
Researchers investigating the outbreak isolated a previously unidentified virus from the blood of infected patients.
This virus became known as chikungunya virus.
Where Did the Name Chikungunya Come From?
The name “chikungunya” comes from a word in the Kimakonde language, spoken in parts of Tanzania and Mozambique.
WHO describes the term as meaning approximately:
“that which bends up”
The expression refers to the stooped or bent posture sometimes adopted by patients experiencing severe joint pain.
The name therefore describes one of the disease’s most characteristic symptoms.
Could Chikungunya Have Existed Before 1952?
Almost certainly.
Researchers reviewing historical medical records have suggested that some epidemics previously described as dengue may actually have been chikungunya.
Before laboratory testing became available, distinguishing the two diseases was difficult.
Both can cause:
- Fever
- Rash
- Headache
- Muscle pain
- Mosquito-associated outbreaks
However, the unusually intense and persistent joint pain of chikungunya provides an important historical clue.
A modern historical review found that some nineteenth and early twentieth-century descriptions of supposed dengue outbreaks were compatible with chikungunya.
Chikungunya Spreads Through Africa and Asia
After its identification in East Africa, chikungunya was recognized in additional parts of Africa and Asia.
Different genetic lineages of the virus became established.
Major historical lineages include:
- West African lineage
- East/Central/South African lineage
- Asian lineage
A later Indian Ocean lineage developed from the East/Central/South African group.
For decades, outbreaks occurred periodically rather than continuously.
Chikungunya in India
India experienced important chikungunya outbreaks during the 1960s and 1970s.
The disease then became relatively quiet in the country for several decades.
When chikungunya returned during the major global resurgence beginning in the mid-2000s, India became one of the countries experiencing very large numbers of cases.
2004: Chikungunya Begins a Major Global Resurgence
A major turning point occurred in 2004, when a large outbreak began in coastal Kenya.
The virus subsequently spread through islands of the Indian Ocean.
This marked the beginning of a period during which chikungunya expanded much more aggressively across the world.
2005 to 2006: The La Réunion Epidemic
One of the most important modern chikungunya outbreaks occurred on La Réunion, a French island in the Indian Ocean.
Hundreds of thousands of infections occurred during the 2005 to 2006 epidemic.
The outbreak demonstrated that chikungunya could infect a very large proportion of a susceptible population.
It also revealed the importance of another mosquito vector:
Aedes albopictus, commonly known as the Asian tiger mosquito.
Historically, Aedes aegypti had been considered the principal urban chikungunya vector.
On La Réunion, however, Aedes albopictus became a highly effective transmitter.
Viral Evolution Helped Chikungunya Spread
During the Indian Ocean epidemic, scientists identified genetic changes in the chikungunya virus associated with more efficient transmission by Aedes albopictus.
One particularly well-studied change affected the viral E1 envelope protein.
This demonstrated something important about emerging infectious diseases.
A relatively small genetic change in a virus can sometimes alter how efficiently it is transmitted by a particular mosquito species.
The importance of Aedes albopictus was especially concerning because this mosquito had already expanded far beyond tropical Asia into:
- Europe
- North America
- South America
- Other temperate regions
2007: Chikungunya Reaches Mainland Europe
In August 2007, northern Italy experienced the first documented autochthonous chikungunya outbreak in mainland Europe.
More than 200 laboratory-confirmed infections were identified near Ravenna.
The virus had apparently been introduced by a traveler returning from India.
Local Aedes albopictus mosquitoes then transmitted the virus within Italy.
This outbreak was historically important because it demonstrated that chikungunya transmission was not restricted to tropical climates.
Where competent mosquitoes are present during sufficiently warm conditions, imported infections can potentially initiate local outbreaks.
2010: Local Transmission Occurs in France
France documented locally acquired chikungunya infections in 2010.
Additional locally transmitted outbreaks occurred in later years.
These events reinforced concerns that southern Europe could experience periodic chikungunya transmission because Aedes albopictus had become established across large areas.
2013: Chikungunya Reaches the Americas
For decades, the Western Hemisphere had experienced travel-associated chikungunya infections but no established local mosquito transmission.
That changed in late 2013.
The first documented locally transmitted chikungunya infections in the Western Hemisphere occurred on Saint Martin in the Caribbean.
Cases began during approximately October 2013 and were formally reported internationally in December.
The virus then spread extraordinarily quickly across the Caribbean and mainland Americas.
2014: Explosive Spread Across the Americas
Within months of the Saint Martin outbreak, chikungunya had spread to numerous Caribbean islands and parts of South America.
By May 2014, more than 100,000 suspected infections had already been reported across affected Caribbean and South American areas.
Later that year, the number of infections across the region grew dramatically.
The rapid expansion was made possible by:
- Large susceptible populations
- Widespread Aedes aegypti
- International travel
- Suitable tropical climates
- Urban mosquito breeding
2014: First Local Transmission in the Continental United States
The first locally acquired chikungunya case in the continental United States was confirmed in Florida in 2014.
The patient had not recently traveled to an endemic area, demonstrating that infection had been acquired from a mosquito within Florida.
Local transmission was later also identified in Texas.
Chikungunya Becomes Nationally Notifiable in the United States
Chikungunya became a nationally notifiable condition in the United States in 2015.
States and local health departments report confirmed and probable cases to CDC through national arbovirus surveillance systems.
2023: The First Chikungunya Vaccine Is Approved in the United States
A major milestone occurred on November 9, 2023.
The FDA approved IXCHIQ, manufactured by Valneva, making it the first chikungunya vaccine approved in the United States.
IXCHIQ was a live attenuated vaccine initially approved for adults aged 18 years and older who were at increased risk of chikungunya exposure.
This was historically significant because scientists had been pursuing a chikungunya vaccine for decades.
However, later postmarketing safety findings substantially changed its U.S. status.
February 2025: VIMKUNYA Becomes the Second U.S. Chikungunya Vaccine
On February 14, 2025, the FDA approved VIMKUNYA, manufactured by Bavarian Nordic.
Unlike IXCHIQ, VIMKUNYA does not contain live chikungunya virus.
It is a recombinant virus-like particle vaccine.
VIMKUNYA is approved for people aged 12 years and older.
2025: Safety Concerns Emerge With IXCHIQ
Postmarketing surveillance identified reports of serious adverse events following administration of IXCHIQ, particularly among older adults.
In May 2025, FDA and CDC recommended pausing use of IXCHIQ in people aged 60 years and older while the reports were investigated.
As of May 7, 2025, 17 serious adverse events had been reported among vaccine recipients aged 62 through 89 years, including two deaths, although reports to passive surveillance systems do not automatically establish causation.
Further investigation identified serious chikungunya-like illnesses after vaccination.
August 2025: FDA Suspends the IXCHIQ License
On August 22, 2025, the FDA suspended the biologics license for IXCHIQ because of serious safety concerns.
FDA reported that the vaccine appeared capable of causing serious chikungunya-like illness in some recipients.
At the time of the suspension, more than 20 serious adverse events consistent with chikungunya-like disease had been reported, and one fatal encephalitis case was directly linked to the vaccine strain using testing of cerebrospinal fluid.
January 2026: IXCHIQ Is Withdrawn in the United States
The accelerated approval for IXCHIQ was formally listed by FDA as withdrawn on January 29, 2026.
Therefore, IXCHIQ should not be presented as a currently available U.S. chikungunya vaccine.
As of September 2026, VIMKUNYA is the chikungunya vaccine available in the United States.
What Happened Globally in 2025?
Chikungunya experienced a substantial international resurgence during 2025.
WHO reported that 502,264 chikungunya cases and 186 deaths were reported globally from 41 countries and territories during 2025.
Major outbreaks affected several regions.
The Indian Ocean region experienced especially important activity, including a major outbreak on La Réunion after years of limited transmission.
WHO reported more than 54,000 confirmed cases and 40 deaths on La Réunion during 2025 by mid-September.
What Is the Chikungunya Situation in 2026?
WHO’s rapid risk assessment dated April 24, 2026 classified the overall global chikungunya risk as:
Moderate
Between January 1 and March 31, 2026, chikungunya transmission had been reported by 18 countries.
Most reported cases during that period came from the Americas, particularly Brazil and Bolivia.
Chikungunya therefore remains an actively emerging and re-emerging mosquito-borne disease.
How Does Chikungunya Virus Infect the Body?
Infection usually begins when an infected mosquito bites a person.
Virus-containing mosquito saliva enters the skin.
Chikungunya virus begins replicating in susceptible cells.
The virus can infect cells associated with:
- Skin
- Fibroblasts
- Muscle
- Joints
- Connective tissues
- Immune system
The virus then enters the bloodstream.
This stage is called viremia.
During the early illness, viral concentrations in blood can become high enough that another mosquito feeding on the infected person can acquire the virus.
Why Does Chikungunya Cause Such Severe Joint Pain?
Joint disease is central to chikungunya.
During acute infection, the virus and the immune response trigger substantial inflammation around:
- Joints
- Tendons
- Muscles
- Connective tissue
Inflammatory signaling produces pain and swelling.
Commonly affected joints include:
- Fingers
- Wrists
- Ankles
- Feet
- Knees
- Elbows
- Shoulders
Joint symptoms are often bilateral and symmetric, meaning similar joints on both sides of the body may hurt simultaneously.
For some patients, inflammation continues or returns after the acute infection resolves.
Which Mosquitoes Spread Chikungunya?
The two most important mosquito species are:
Aedes aegypti
Often called the yellow fever mosquito.
It is highly adapted to living near humans and commonly breeds in artificial containers containing water.
Aedes albopictus
Often called the Asian tiger mosquito.
This mosquito can tolerate a wider range of climates and has expanded extensively into temperate regions.
Both species can also transmit:
- Dengue
- Zika virus
Do Chikungunya Mosquitoes Bite During the Day?
Yes.
Aedes aegypti and Aedes albopictus are particularly active during daylight hours.
Biting can occur throughout the day, with activity often increasing during:
- Early morning
- Late afternoon
However, CDC notes that chikungunya-carrying mosquitoes can bite during both day and night, so mosquito protection should not be limited to evening hours.
How Does Chikungunya Spread Between Humans and Mosquitoes?
The main urban transmission cycle is:
infected human → mosquito → another human
A mosquito bites a person who has chikungunya virus circulating in their blood.
The mosquito becomes infected.
After the virus replicates inside the mosquito, the mosquito can transmit CHIKV to another person during a later bite.
Humans therefore act as important amplifying hosts during major outbreaks.
Is There a Jungle Transmission Cycle?
Yes.
In parts of sub-Saharan Africa, chikungunya virus can circulate in a sylvatic cycle involving:
- Non-human primates
- Forest-dwelling mosquitoes
Humans can occasionally become infected through spillover from this natural cycle.
Large urban outbreaks, however, usually involve human-to-mosquito-to-human transmission.
Can Chikungunya Spread Directly From Person to Person?
Not through normal social contact.
Chikungunya does not normally spread through:
- Coughing
- Sneezing
- Touching
- Hugging
- Sharing food
- Being in the same room
The mosquito is normally required to carry the virus between people.
Can Chikungunya Spread Through Blood?
Potential bloodborne transmission is possible because infected people can have high concentrations of virus in their bloodstream during acute illness.
CDC identifies:
- Blood transfusion as a probable possible route
- Laboratory exposure as a documented occupational risk
These routes are uncommon compared with mosquito transmission.
Can Chikungunya Spread During Pregnancy?
Yes, but transmission during pregnancy is uncommon overall.
A pregnant woman can rarely transmit chikungunya virus to the fetus before birth.
The greatest concern occurs when the mother has chikungunya virus circulating in her blood around the time of delivery.
Intrapartum transmission can result in severe neonatal disease.
Can Chikungunya Spread Through Breast Milk?
CDC states that chikungunya virus has not been identified in breast milk, and there have been no reported cases of infants acquiring chikungunya through breastfeeding.
The known benefits of breastfeeding generally remain important.
When Is an Infected Person Most Likely to Infect Mosquitoes?
Virus levels in the blood are highest during the early illness.
CDC reports that people can have sufficient viremia to infect mosquitoes during approximately the first week of illness.
Someone with chikungunya should therefore make an extra effort to avoid mosquito bites during this period.
Otherwise, mosquitoes could bite the infected person and subsequently infect other people.
What Is the Incubation Period?
Symptoms commonly develop approximately:
3 to 7 days after an infected mosquito bite
CDC gives a possible range of approximately:
1 to 12 days.
WHO commonly describes an average interval of approximately 4 to 8 days with a range of 2 to 12 days.
Differences between these ranges reflect different datasets rather than fundamentally conflicting disease patterns.
Does Everyone Infected With Chikungunya Develop Symptoms?
Most infected people do.
CDC’s Yellow Book estimates that approximately 15% to 35% of infected people may remain asymptomatic.
This means symptomatic infection is considerably more common with chikungunya than with certain other mosquito-borne diseases such as Zika.
What Are the First Symptoms of Chikungunya?
Chikungunya often begins suddenly.
The two defining symptoms are:
High Fever
Fever frequently exceeds:
39°C, or approximately 102°F
Severe Joint Pain
Pain may begin abruptly and involve several joints simultaneously.
The combination of:
sudden high fever + severe polyarthralgia
is one of the strongest clinical clues suggesting chikungunya.
What Other Symptoms Occur?
Additional symptoms can include:
- Headache
- Muscle pain
- Joint swelling
- Arthritis
- Nausea
- Vomiting
- Conjunctivitis
- Fatigue
- Maculopapular rash
Some patients feel profoundly weak during the acute illness.
What Does the Chikungunya Rash Look Like?
The rash is generally maculopapular or morbilliform.
This means it may include:
- Flat reddish areas
- Small raised bumps
- Widespread patches
The rash commonly affects:
- Trunk
- Arms
- Legs
It can also involve:
- Face
- Palms
- Soles
The rash may itch.
Rash appearance alone cannot reliably distinguish chikungunya from dengue, Zika, measles, drug reactions, and other illnesses.
How Long Does Acute Chikungunya Last?
Acute symptoms generally improve within approximately:
7 to 10 days
The fever usually lasts less than one week.
However, joint symptoms can last far longer.
This distinction is extremely important.
A patient may no longer have active acute viral illness but continue experiencing disabling musculoskeletal symptoms.
Why Is Chikungunya Joint Pain So Important?
For some patients, joint pain is severe enough to interfere with:
- Walking
- Standing
- Dressing
- Writing
- Working
- Sleeping
- Opening containers
- Climbing stairs
- Caring for children
Hands, wrists, ankles, and feet can be particularly painful.
Some people describe stiffness resembling inflammatory arthritis.
Can Joint Pain Last for Months?
Yes.
Persistent joint symptoms are one of the defining long-term complications.
CDC notes that patients can experience:
- Persistent polyarthralgia
- Polyarthritis
- Tenosynovitis
- Recurrent joint inflammation
- Raynaud-type symptoms
- Prolonged fatigue
for months or years after infection.
How Common Is Chronic Joint Pain?
Estimates vary widely.
Studies reviewed by CDC have reported persistent joint symptoms in approximately 5% to 80% of patients, depending on:
- Population studied
- Age
- Follow-up duration
- Definition of persistent symptoms
- Underlying joint disease
- Severity of the original infection
Because the estimates vary so substantially, no single percentage accurately represents every population.
Can Chikungunya Cause Chronic Arthritis?
Yes.
Some patients develop persistent inflammatory arthritis after infection.
Symptoms may resemble:
- Rheumatoid arthritis
- Other inflammatory polyarthritis disorders
Possible features include:
- Morning stiffness
- Joint swelling
- Symmetric pain
- Reduced joint movement
- Tendon inflammation
Patients with prolonged inflammatory symptoms may benefit from evaluation by a rheumatologist.
Who Is More Likely to Develop Persistent Joint Problems?
Research suggests that long-term symptoms may be more common among people who:
- Are older
- Have severe acute joint symptoms
- Have existing joint disease
- Have certain underlying conditions
However, persistent joint symptoms can also affect previously healthy younger adults.
Can Chikungunya Become a Chronic Infection?
Persistent joint symptoms do not necessarily mean that large amounts of actively replicating virus remain circulating in the bloodstream for months.
The chronic disease appears to involve complex interactions among:
- Persistent immune activation
- Inflammation
- Tissue responses
- Possibly persistent viral material in certain tissues
Research continues into the exact mechanisms responsible for chronic chikungunya arthritis.
What Serious Complications Can Chikungunya Cause?
Severe complications are uncommon but well documented.
CDC lists rare complications involving several organ systems.
These include:
Neurological complications
- Meningoencephalitis
- Myelitis
- Guillain-Barré syndrome
- Cranial nerve palsies
Eye complications
- Uveitis
- Retinitis
Heart complications
- Myocarditis
Liver complications
- Hepatitis
Kidney complications
- Nephritis
- Acute kidney disease
Skin complications
- Severe bullous skin lesions
Other complications
- Hemorrhagic manifestations
Can Chikungunya Affect the Brain?
Yes.
Rare neuroinvasive disease can cause inflammation involving the brain, spinal cord, or peripheral nerves.
Possible symptoms include:
- Confusion
- Severe headache
- Seizures
- Altered consciousness
- Weakness
- Paralysis
- Abnormal coordination
These symptoms require urgent medical evaluation.
Can Chikungunya Cause Guillain-Barré Syndrome?
Yes.
Guillain-Barré syndrome has been reported as a rare neurological complication.
GBS occurs when the immune system damages peripheral nerves.
Symptoms can include:
- Tingling
- Progressive weakness
- Difficulty walking
- Facial weakness
- Difficulty swallowing
- Breathing problems
Severe cases require hospitalization.
Can Chikungunya Affect the Heart?
Yes.
Myocarditis, inflammation of the heart muscle, is a recognized but uncommon complication.
Symptoms may include:
- Chest pain
- Shortness of breath
- Palpitations
- Weakness
- Fainting
Older patients and people with cardiovascular disease may be particularly vulnerable to serious complications.
Can Chikungunya Cause Death?
Yes, but death is rare relative to the total number of infections.
Deaths occur disproportionately among:
- Older adults
- Newborns
- People with significant underlying illnesses
- Patients who develop severe neurological or cardiovascular complications
The very large number of infections during major epidemics means that even a low individual fatality risk can result in deaths at population level.
Who Is at Highest Risk of Severe Chikungunya?
CDC identifies several important groups:
Newborns
Especially babies infected around the time of birth.
Adults Over 65
Risk increases with age.
People With Hypertension
Underlying cardiovascular stress can increase vulnerability.
People With Diabetes
Diabetes may increase the likelihood of serious disease.
People With Cardiovascular Disease
Pre-existing cardiac disease can complicate infection.
Chikungunya During Pregnancy
Most pregnant women with chikungunya experience an illness similar to other adults.
Most infections during pregnancy do not result in fetal infection.
The most dangerous period is when the mother becomes viremic very close to delivery.
Why Is Infection Around Delivery Dangerous?
If the mother has high levels of chikungunya virus in her blood during childbirth, the newborn can acquire the infection.
Severe neonatal chikungunya can cause:
- Fever
- Poor feeding
- Skin abnormalities
- Bleeding
- Myocardial disease
- Neurological disease
These babies may require intensive hospital care.
Can Chikungunya Cause Miscarriage?
Rare spontaneous abortions following first-trimester maternal infection have been reported.
However, most maternal infections do not result in pregnancy loss or congenital infection.
Is Chikungunya Like Zika During Pregnancy?
No.
Both viruses can be transmitted by Aedes mosquitoes, but their pregnancy risks differ significantly.
Zika virus has a well-established association with congenital brain and eye abnormalities and congenital Zika syndrome.
Chikungunya is particularly concerning when maternal infection occurs around the time of delivery because of the risk of severe neonatal infection.
Chikungunya in Babies and Children
Children can develop:
- Fever
- Rash
- Joint symptoms
- Irritability
- Poor feeding
Young infants can develop more severe manifestations.
Newborns infected around delivery or through mosquito bites during the first weeks of life are among the groups at greatest risk of serious disease.
How Is Chikungunya Diagnosed?
Symptoms alone are not sufficient for a definitive diagnosis.
Laboratory testing is particularly useful because chikungunya can closely resemble:
- Dengue
- Zika
- Mayaro virus infection
- Malaria
- Leptospirosis
- Measles
- Rubella
- Parvovirus infection
- Other viral illnesses
- Rheumatologic disease
The correct test depends on how long the patient has been ill.
RT-PCR Testing
During the acute stage, chikungunya viral RNA can often be detected using:
reverse-transcription polymerase chain reaction, or RT-PCR
CDC states that viral RNA can often be detected in serum during the first 8 days of illness.
A positive molecular test strongly supports acute infection.
Antibody Testing
As the immune system responds, it produces antibodies against chikungunya virus.
Important antibody types include:
- IgM
- Neutralizing antibodies
Chikungunya-specific IgM antibodies generally begin appearing toward the end of the first week of illness.
Can an Early Chikungunya Test Be Negative?
Yes.
A person tested too early may not yet have detectable antibodies.
If acute testing is negative but clinical suspicion remains high, a later convalescent sample may be needed.
CDC recommends convalescent testing when necessary to definitively rule out infection after an initially negative acute-phase result.
Why Are Positive IgM Results Sometimes Confirmed?
False-positive chikungunya IgM results can occur.
Antibodies may occasionally react with related alphaviruses.
CDC therefore recommends confirmation of positive chikungunya IgM results with neutralizing antibody testing when appropriate.
Can Chikungunya and Dengue Occur Together?
Yes.
The same Aedes mosquitoes can carry both viruses, and co-infections can occasionally occur.
This is clinically important because treatment precautions differ.
A patient with suspected chikungunya should generally be managed as though dengue might also be present until dengue has been ruled out.
How Can Chikungunya Be Distinguished From Dengue?
Both can cause:
- Fever
- Headache
- Muscle aches
- Rash
- Low blood counts
However, chikungunya is generally more strongly associated with:
- Severe joint pain
- Arthritis
- Joint swelling
- Prolonged rheumatologic symptoms
Dengue is more strongly associated with:
- Significant thrombocytopenia
- Bleeding
- Plasma leakage
- Shock
- Severe hemorrhagic complications
Laboratory testing is often needed.
How Is Chikungunya Different From Zika?
Chikungunya usually produces much more severe joint pain and fever.
Zika infection is frequently asymptomatic or mild but is particularly important because of fetal complications during pregnancy.
| Feature | Chikungunya | Zika |
|---|---|---|
| Main vector | Aedes mosquitoes | Aedes mosquitoes |
| Fever | Often high | Usually mild |
| Joint pain | Often severe | Usually milder |
| Joint swelling | Common | Less prominent |
| Rash | Common | Common |
| Conjunctivitis | Can occur | Common |
| Chronic joint symptoms | Important | Less characteristic |
| Major pregnancy concern | Severe neonatal infection near delivery | Congenital Zika syndrome |
| U.S. vaccine | Yes, for selected people | No approved vaccine |
Is Chikungunya a Nationally Notifiable Disease in the United States?
Yes.
Chikungunya became nationally notifiable in 2015.
Healthcare providers and laboratories report cases through state and local health departments, which provide information to CDC.
How Is Chikungunya Treated?
There is currently no specific antiviral medication approved to cure chikungunya.
Treatment is primarily supportive.
Management can include:
- Rest
- Fluids
- Fever control
- Pain management
- Monitoring for complications
- Management of persistent joint symptoms
What Medicine Can Be Used for Fever and Pain?
Because chikungunya can resemble dengue, CDC recommends using:
acetaminophen, also called paracetamol
as the preferred initial medication for fever and pain until dengue has been ruled out.
Why Should Aspirin and NSAIDs Initially Be Avoided?
Dengue can cause serious bleeding.
Medications such as:
- Aspirin
- Ibuprofen
- Naproxen
can increase bleeding risk.
Therefore, a person with suspected chikungunya who may actually have dengue should generally avoid these medications until dengue has been excluded.
Once dengue has been ruled out, NSAIDs may be useful for persistent inflammatory joint pain when medically appropriate.
How Is Chronic Chikungunya Joint Pain Treated?
Management depends on severity and duration.
Options can include:
- NSAIDs when appropriate
- Physical therapy
- Gradual rehabilitation
- Heat or cold therapy depending on symptoms
- Specialist rheumatology evaluation
- Selected corticosteroid therapy in certain patients
CDC notes that NSAIDs, corticosteroids, and physical therapy may help some patients with persistent joint pain.
Long-term medication should be individualized rather than self-directed.
Are Antibiotics Useful?
No.
Chikungunya is caused by a virus.
Antibiotics do not kill chikungunya virus.
They are only useful if a separate bacterial infection is present.
Are Antiviral Drugs Being Developed?
Yes.
Researchers continue investigating antiviral treatments for chikungunya.
However, as of 2026, CDC states that no specific antiviral therapy is available for routine treatment.
Is There a Chikungunya Vaccine?
Yes.
This is a major change from older chikungunya information.
As of 2026, the United States has an available chikungunya vaccine called:
VIMKUNYA
VIMKUNYA is manufactured by Bavarian Nordic.
It was FDA approved in February 2025.
The vaccine is approved for:
people aged 12 years and older
for prevention of disease caused by chikungunya virus.
What Type of Vaccine Is VIMKUNYA?
VIMKUNYA is a recombinant virus-like particle vaccine.
It does not contain live chikungunya virus.
Virus-like particles resemble the outside structure of the virus closely enough to stimulate an immune response but do not contain the complete infectious virus needed to produce ordinary chikungunya infection.
How Many Doses of VIMKUNYA Are Needed?
Current CDC guidance uses:
one 0.8 mL intramuscular dose
There is currently no recommendation for a routine booster dose.
Future recommendations could change as longer-term protection data become available.
Who Should Receive the Chikungunya Vaccine?
CDC recommends VIMKUNYA for people aged 12 years and older who are traveling to a country or territory where a chikungunya outbreak is occurring.
Vaccination is also recommended for laboratory workers who may be exposed to chikungunya virus.
Who May Consider Vaccination?
Vaccination may also be considered for people aged 12 years and older who are traveling or moving to an area that does not currently have an outbreak but has elevated chikungunya risk for U.S. travelers when they plan to remain there for an extended period.
CDC uses approximately:
6 months or longer
as an example of extended travel or residence.
Which Countries Have Elevated Risk for U.S. Travelers?
As of September 2026, CDC identifies the following countries as having elevated risk for U.S. travelers even when an active outbreak is not occurring:
- Brazil
- Colombia
- India
- Indonesia
- Mexico
- Nigeria
- Pakistan
- Peru
- Philippines
- Thailand
Travel recommendations can change as outbreaks develop or resolve.
How Well Does VIMKUNYA Produce an Immune Response?
Clinical trials measured neutralizing antibody responses rather than waiting for large numbers of naturally occurring chikungunya cases.
CDC reports that three weeks after vaccination, seroresponse occurred in approximately:
- 98% of people aged 12 to 64 years
- 87% of people aged 65 years and older
At six months, reported seroresponse rates were approximately:
- 85% among people aged 12 to 64
- 76% among people aged 65 and older
Long-term protection continues to be studied.
What Are the Common Side Effects of VIMKUNYA?
According to FDA prescribing information, the most common reactions among vaccine recipients aged 12 through 64 included:
- Injection-site pain
- Fatigue
- Headache
- Muscle pain
In clinical studies:
- Injection-site pain occurred in 23.7%
- Fatigue occurred in 19.9%
- Headache occurred in 18.0%
- Myalgia occurred in 17.6%
Most reactions were short-lived.
Who Should Not Receive VIMKUNYA?
CDC lists a history of a severe allergic reaction such as anaphylaxis to a vaccine component as a contraindication.
People with special medical circumstances should discuss vaccination with a healthcare professional.
What About Immunocompromised People?
Because VIMKUNYA is not a live vaccine, it does not carry the same theoretical risk as a replicating live vaccine in someone with immune suppression.
However, immunocompromised individuals may produce a weaker immune response.
FDA and CDC therefore advise that altered immune status be considered when evaluating vaccination.
Can Pregnant Women Receive VIMKUNYA?
Current CDC guidance generally recommends deferring chikungunya vaccination until after pregnancy when exposure can reasonably be avoided.
However, when infection risk is high, such as during a significant outbreak and exposure cannot be avoided, the pregnant patient and healthcare professional should discuss:
- Risk from chikungunya infection
- Risk of severe maternal disease
- Risk of infection near delivery
- Potential vaccine benefits
- Available vaccine safety data
What Happened to IXCHIQ?
IXCHIQ has an important place in chikungunya vaccine history because it became the first FDA-approved chikungunya vaccine in November 2023.
It was different from VIMKUNYA.
IXCHIQ contained a live attenuated chikungunya virus.
The vaccine was capable of replicating to a limited extent inside the recipient, producing a strong immune response.
However, postmarketing surveillance identified serious chikungunya-like adverse events.
FDA suspended its biologics license in August 2025.
FDA’s accelerated approval records list the approval as withdrawn effective January 29, 2026.
Therefore, as of September 2026:
| Vaccine | Current U.S. Status |
|---|---|
| VIMKUNYA | Available and FDA approved |
| IXCHIQ | No longer available under its former U.S. approval |
Chikungunya Vaccine Quick Reference
| Question | Current U.S. Information |
|---|---|
| Is there a chikungunya vaccine? | Yes |
| Current vaccine | VIMKUNYA |
| Vaccine type | Recombinant virus-like particle |
| Contains live CHIKV? | No |
| Approved age | 12 years and older |
| Dose | One intramuscular dose |
| Routine booster | None currently recommended |
| Routine vaccine for all Americans? | No |
| Main use | Selected travelers and exposed laboratory workers |
| IXCHIQ current U.S. status | Withdrawn following prior license suspension |
| Vaccine research continuing? | Yes |
How Can Chikungunya Be Prevented?
Vaccination is useful for selected people, but mosquito protection remains extremely important.
This is particularly true because:
- Vaccination is not recommended for everyone
- Children under 12 are not currently covered by the U.S. VIMKUNYA indication
- Mosquitoes that transmit chikungunya also transmit other diseases
Use Insect Repellent
CDC recommends using an appropriate EPA-registered insect repellent.
Common active ingredients can include:
- DEET
- Picaridin
- IR3535
- Oil of lemon eucalyptus or PMD in eligible age groups
- 2-undecanone
Always follow product instructions.
Wear Protective Clothing
When possible, wear:
- Long-sleeved shirts
- Long pants
- Socks
- Shoes
Reducing exposed skin can reduce mosquito bites.
Use Permethrin-Treated Clothing and Gear
Permethrin can be applied to appropriate:
- Clothing
- Boots
- Mosquito nets
- Outdoor gear
according to product instructions.
Permethrin products intended for clothing should not be applied directly to skin.
Use Window and Door Screens
Aedes mosquitoes frequently live close to humans.
Well-maintained screens can reduce mosquito entry into homes.
Air-conditioned environments can also reduce exposure when doors and windows remain closed.
Remove Standing Water
Aedes mosquitoes often breed in relatively small containers.
Potential breeding sites include:
- Buckets
- Tires
- Flowerpots
- Bottles
- Water-storage containers
- Bird baths
- Outdoor toys
- Gutters
- Plant trays
Containers should be:
- Emptied
- Scrubbed
- Covered
- Turned over
- Discarded
when possible.
Should Someone With Chikungunya Still Avoid Mosquito Bites?
Yes.
This is extremely important during the first week of illness.
A mosquito that bites an infected patient can acquire the virus and later transmit it to someone else.
CDC therefore recommends preventing mosquito bites during the early illness to interrupt further transmission.
Can Mosquito Nets Help?
Yes.
Aedes mosquitoes are mainly daytime biters, but mosquito nets remain useful for people who sleep during the day, including:
- Infants
- Sick patients
- Older people
- Shift workers
WHO specifically recommends insecticide-treated nets for people sleeping during periods when Aedes mosquitoes may be active.
Does Air Conditioning Help?
Air conditioning can reduce mosquito exposure when it allows windows and doors to remain closed.
It should be combined with:
- Screens
- Mosquito control
- Repellent
- Elimination of breeding sites
Where Does Chikungunya Occur?
Chikungunya has now been reported across:
- Africa
- Asia
- Indian Ocean islands
- Pacific islands
- Caribbean
- Central America
- South America
- Parts of North America
- Parts of Europe
WHO reported that by the end of 2024, 119 countries and territories had documented current or previous local chikungunya transmission.
Why Is Chikungunya Expanding Geographically?
Several factors contribute.
Expansion of Aedes Mosquitoes
Aedes albopictus has spread into regions where it did not historically occur.
Urbanization
Dense urban communities provide:
- Large numbers of human hosts
- Artificial water containers
- Suitable mosquito habitats
International Travel
An infected traveler can introduce the virus into a new area while still viremic.
Climate and Weather
Temperature and rainfall influence mosquito abundance and the speed at which viruses develop inside mosquitoes.
Limited Population Immunity
When chikungunya enters a population that has rarely or never encountered it, large outbreaks can occur.
WHO has identified these factors as contributing to the continuing international risk of chikungunya spread.
Chikungunya in the United States
Most U.S. chikungunya infections are associated with international travel.
Local mosquito transmission has nevertheless occurred.
CDC reports locally acquired cases in:
- Florida in 2014
- Texas in 2015
- Florida and New York in 2025
What Is the Current U.S. Situation in 2026?
As of September 15, 2026, CDC reported:
- 0 locally acquired cases in U.S. states during 2026
- 116 travel-associated or other non-local cases in U.S. states
- 0 locally acquired cases in U.S. territories
- 1 travel-associated case in a U.S. territory
These figures are preliminary and can change.
The most recent locally acquired U.S. state cases occurred in 2025.
Can Chikungunya Become Established in New U.S. Areas?
Potentially.
The mosquitoes capable of transmitting chikungunya are present in parts of the United States.
Local transmission can occur when:
- An infected traveler returns while viremic.
- A local mosquito bites that person.
- The mosquito becomes infected.
- The mosquito later bites another person.
Whether a larger outbreak develops depends on:
- Mosquito density
- Weather
- Population immunity
- Vector-control efforts
- Human behavior
- Timing of introduction
Is Chikungunya Seasonal?
Seasonality varies by location.
Outbreaks often increase when warm temperatures and rainfall support Aedes mosquito populations.
In tropical regions, transmission can occur for extended periods.
In temperate regions, local transmission is generally more likely during warmer mosquito-active months.
Can Someone Get Chikungunya Twice?
Most evidence indicates that infection produces a strong and long-lasting immune response.
True reinfection appears to be uncommon.
However, someone experiencing recurrent joint pain months after infection is not necessarily experiencing a new chikungunya infection.
Chronic or relapsing rheumatologic symptoms can occur after the original disease.
Is Chikungunya the Same as Dengue?
No.
They are caused by completely different viruses.
However, both are often transmitted by the same mosquito species.
| Feature | Chikungunya | Dengue |
|---|---|---|
| Virus family | Togaviridae | Flaviviridae |
| Main vector | Aedes mosquitoes | Aedes mosquitoes |
| High fever | Common | Common |
| Severe joint pain | Highly characteristic | Can occur |
| Chronic joint pain | Important complication | Less characteristic |
| Serious bleeding | Uncommon | Important in severe dengue |
| Shock | Rare | Can occur in severe dengue |
| Vaccine available in U.S. | VIMKUNYA for selected people | Dengue vaccine indications differ |
| Specific antiviral treatment | No | No |
Because the two diseases overlap clinically, dengue must be considered before medications such as aspirin or NSAIDs are used.
Is Chikungunya the Same as Zika?
No.
Chikungunya and Zika:
- Are caused by different viruses
- Belong to different virus families
- Produce different major complications
Their similarity comes partly from sharing the same mosquito vectors.
Chikungunya is particularly associated with severe and prolonged joint pain.
Zika is particularly associated with congenital abnormalities when infection occurs during pregnancy.
Is Chikungunya the Same as Malaria?
No.
Malaria is caused by Plasmodium parasites transmitted primarily by Anopheles mosquitoes.
Chikungunya is caused by a virus transmitted primarily by Aedes mosquitoes.
The diseases require completely different testing and treatment.
When Should Someone Seek Medical Care?
Medical evaluation is appropriate when a person develops:
- Sudden fever
- Severe joint pain
- Joint swelling
- Rash
- Severe fatigue
after living in or traveling through an area with chikungunya transmission.
Tell the healthcare professional:
- Countries visited
- Dates of travel
- Mosquito exposure
- Symptom onset date
- Pregnancy status
- Underlying medical conditions
- Whether dengue or malaria exposure is possible
When Is Chikungunya an Emergency?
Seek urgent medical attention for symptoms such as:
- Difficulty breathing
- Severe chest pain
- Confusion
- Loss of consciousness
- Seizures
- Severe weakness
- Persistent vomiting
- Inability to drink fluids
- Signs of dehydration
- Unusual bleeding
- Severe headache with neurological changes
- Rapid deterioration
Newborns, older adults, pregnant patients near delivery, and people with serious underlying medical conditions deserve particularly prompt assessment.
Frequently Asked Questions About Chikungunya
What causes chikungunya?
Chikungunya is caused by chikungunya virus, an alphavirus belonging to the Togaviridae family.
What does chikungunya mean?
The name comes from the Kimakonde language and is commonly translated as “that which bends up,” referring to the bent posture caused by severe joint pain.
When was chikungunya discovered?
The first clearly recognized outbreak occurred in southern Tanzania during 1952 to 1953.
How is chikungunya transmitted?
Primarily through bites from infected Aedes aegypti and Aedes albopictus mosquitoes.
Can chikungunya spread by touching someone?
No.
It does not normally spread through touching, coughing, sneezing, or ordinary social contact.
Can a mosquito get chikungunya from an infected person?
Yes.
During the first week of illness, virus concentrations in the blood can be high enough to infect mosquitoes.
How quickly do symptoms begin?
Usually within approximately 3 to 7 days, although the possible range extends to approximately 1 to 12 days.
What are the two most common symptoms?
The two defining symptoms are:
- Fever
- Joint pain
How high can the fever become?
Chikungunya frequently produces temperatures above approximately 39°C or 102°F.
Why does chikungunya cause joint pain?
Viral infection and immune inflammation affect joints, connective tissue, tendons, and surrounding structures.
Which joints are usually affected?
Common sites include:
- Hands
- Wrists
- Ankles
- Feet
- Knees
Joint symptoms are frequently bilateral and symmetric.
How long does chikungunya last?
The acute illness usually improves within approximately 7 to 10 days.
Joint symptoms can last much longer.
Can chikungunya joint pain last for years?
Yes.
Some patients experience recurrent or persistent rheumatologic symptoms for months or years.
Does everyone with chikungunya have symptoms?
No.
CDC estimates that approximately 15% to 35% of infected people may remain asymptomatic.
Is chikungunya deadly?
Death is uncommon, but severe and fatal disease can occur.
Older adults, newborns, and people with significant underlying illnesses are at greater risk.
Can chikungunya affect the brain?
Yes.
Rare complications include encephalitis, meningoencephalitis, myelitis, and other neurological disease.
Can chikungunya cause Guillain-Barré syndrome?
Yes.
It is a recognized but uncommon neurological complication.
Can chikungunya damage the heart?
Yes.
Myocarditis has been reported.
Can chikungunya cause blindness?
Serious eye complications such as uveitis and retinitis can occur, although they are uncommon.
Severe eye symptoms require specialist evaluation.
Can pregnant women get chikungunya?
Yes.
Pregnancy does not prevent infection.
The most important fetal and neonatal risk occurs when the mother is infected close to delivery.
Can a mother transmit chikungunya to her baby?
Yes.
Intrapartum transmission can occur and may produce severe neonatal illness.
Can chikungunya spread through breastfeeding?
No breastfeeding-associated transmission has been reported, and CDC states the virus has not been identified in breast milk.
Is there a blood test for chikungunya?
Yes.
Testing can include:
- RT-PCR
- IgM antibody testing
- Neutralizing antibody testing
When is PCR useful?
Viral RNA can often be detected during approximately the first 8 days of illness.
When are antibodies detectable?
Chikungunya-specific antibodies usually begin developing toward the end of the first week.
Is there a cure for chikungunya?
There is no specific approved antiviral cure.
Treatment focuses on symptom relief and management of complications.
Do antibiotics treat chikungunya?
No.
Antibiotics do not treat viral chikungunya infection.
Can I take ibuprofen for chikungunya?
NSAIDs can sometimes help after dengue has been ruled out.
Until then, acetaminophen or paracetamol is generally preferred because dengue can cause bleeding.
Is there a chikungunya vaccine?
Yes.
VIMKUNYA is currently available in the United States.
At what age can VIMKUNYA be given?
FDA approves VIMKUNYA for people aged 12 years and older.
How many doses are needed?
Current CDC guidance recommends a single dose, with no routine booster currently recommended.
Does VIMKUNYA contain live chikungunya virus?
No.
It is a recombinant virus-like particle vaccine.
Is chikungunya vaccination recommended for everyone?
No.
In the United States it is primarily recommended for selected travelers and laboratory workers at meaningful risk of exposure.
What happened to IXCHIQ?
IXCHIQ was the first FDA-approved chikungunya vaccine in 2023.
Postmarketing reports subsequently raised serious safety concerns.
FDA suspended its biologics license in August 2025, and its accelerated approval is listed as withdrawn effective January 29, 2026.
Is chikungunya present in the United States?
Most U.S. cases are travel-associated.
Local transmission has occurred in Florida, Texas, Puerto Rico, the U.S. Virgin Islands, and most recently in Florida and New York in 2025.
Have there been locally acquired U.S. cases in 2026?
As of September 15, 2026, CDC reported zero locally acquired cases in U.S. states during 2026.
Can chikungunya return to an area after years without outbreaks?
Yes.
This occurred dramatically on La Réunion during 2024 and 2025.
Large susceptible populations can allow transmission to return after long periods of limited activity.
Is chikungunya increasing worldwide?
Chikungunya activity varies greatly from year to year and region to region.
WHO documented a major resurgence in several regions during 2025 and rated the global public-health risk as moderate in April 2026.
Can chikungunya be eradicated?
Eradication would be extremely difficult because:
- Aedes mosquitoes are geographically widespread
- International travelers can carry the virus between regions
- Sylvatic transmission occurs in parts of Africa
- Large susceptible populations remain
- Mosquito control is difficult to sustain
Public-health strategies therefore focus on vaccination for appropriate people, mosquito control, surveillance, rapid outbreak detection, and personal bite prevention.
Why Chikungunya Remains an Important Global Disease
Chikungunya has undergone one of the most striking geographic expansions among modern mosquito-borne viruses.
The disease was formally recognized during an outbreak in southern Tanzania in 1952 and 1953.
Its name reflected the severe joint pain that caused sick patients to walk in a bent posture.
For several decades, chikungunya remained primarily an African and Asian disease.
Then the situation changed.
A large outbreak beginning in Kenya in 2004 spread into the Indian Ocean.
The enormous La Réunion epidemic during 2005 and 2006 demonstrated the ability of Aedes albopictus to drive large outbreaks.
In 2007, imported virus initiated local transmission in Italy, proving that chikungunya could produce outbreaks in temperate Europe.
In late 2013, local transmission appeared on Saint Martin.
Within months, chikungunya had spread across much of the Caribbean and into mainland America.
Florida documented locally acquired infection in 2014.
Texas followed in 2015.
The United States again recorded locally acquired state cases in Florida and New York in 2025.
Meanwhile, the disease continued re-emerging in previously affected regions.
The 2025 epidemic on La Réunion occurred almost two decades after the island’s famous 2005 to 2006 outbreak.
WHO documented more than half a million reported chikungunya cases globally during 2025 and continued to classify chikungunya as a significant international public-health threat during 2026.
At the same time, prevention entered a new era.
For most of chikungunya’s known history, mosquito avoidance was the only direct method of preventing infection.
That changed in November 2023 when IXCHIQ became the first FDA-approved chikungunya vaccine.
The history of that vaccine also demonstrated the importance of continued safety surveillance after approval.
Serious chikungunya-like adverse events identified during real-world use led FDA to first restrict and then suspend IXCHIQ. Its U.S. accelerated approval was subsequently withdrawn in January 2026.
The current U.S. option is VIMKUNYA, a non-live recombinant virus-like particle vaccine approved for people aged 12 years and older and recommended primarily for travelers and laboratory workers with meaningful exposure risk.
Despite these advances, chikungunya remains difficult to control.
The mosquitoes that transmit it live close to humans.
They breed in small collections of water.
They bite during daylight hours.
They can also transmit dengue and Zika.
International travelers can unknowingly introduce chikungunya into regions where competent mosquitoes are already present.
Most importantly, chikungunya is not simply a short febrile illness.
For many patients, the fever disappears within days.
The joint pain may not.
Months or years of arthritis, stiffness, fatigue, and reduced mobility can follow what initially appeared to be a temporary mosquito-borne infection.
That chronic burden distinguishes chikungunya from many other acute arboviral diseases.
Modern chikungunya prevention therefore depends on several strategies working together:
- Surveillance
- Rapid outbreak recognition
- Mosquito control
- Elimination of breeding sites
- Personal mosquito protection
- Appropriate vaccination
- Correct diagnosis
- Differentiation from dengue
- Supportive treatment
- Long-term management of chronic joint disease
More than seven decades after chikungunya virus was identified in Tanzania, the disease remains a powerful example of how viral evolution, mosquito ecology, travel, climate, population immunity, and urbanization can transform a regional infection into a global health concern.
Medical, vaccine, epidemiological, and treatment information reviewed against CDC, FDA, WHO, ECDC, and peer-reviewed sources available through September 2026.
Official Sources
- CDC: About Chikungunya
- CDC: Clinical Signs and Symptoms
- CDC: Clinical Testing and Diagnosis
- CDC: Treatment and Prevention
- CDC: Vaccine Information for Healthcare Providers
- FDA: VIMKUNYA
- FDA: IXCHIQ Permanent Discontinuation
- FDA: Withdrawn Infectious Disease Accelerated Approvals
- WHO: Chikungunya Global Rapid Risk Assessment